As Merck MRK is gearing up to report its fourth-quarter and full-year 2025 results on Feb. 3, investors' focus is likely to ...

Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day simple moving averages (SMAs) since early November, indicating sustained ...

A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, Keytruda. The drug contributes over half of the company’s pharmaceutical ...

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...

Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, TD Cowen ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.